Shares of InterMune (ITMN -12.5%) add to yesterday's selloff after the Institute for Quality and...
Shares of InterMune (ITMN -12.5%) add to yesterday's selloff after the Institute for Quality and Efficiency in Health Care concluded that no additional benefit could be found for its idiopathic pulmonary fibrosis drug Esbriet, also known as pirfenidone.
From other sites
at CNBC.com (Sep 15, 2014)
at CNBC.com (Sep 11, 2014)
at MarketWatch.com (Sep 11, 2014)
at CNBC.com (Aug 28, 2014)
at CNBC.com (Aug 26, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs